Last reviewed · How we verify

Haemostatic solution "Haemoblock" application

Ryazan State Medical University · FDA-approved active Small molecule

Haemoblock is a topical haemostatic agent that promotes blood clotting and wound hemostasis through physical and biochemical mechanisms.

Haemoblock is a topical haemostatic agent that promotes blood clotting and wound hemostasis through physical and biochemical mechanisms. Used for Surgical hemostasis and control of bleeding during surgical procedures, Wound hemostasis in general and specialized surgery.

At a glance

Generic nameHaemostatic solution "Haemoblock" application
Also known as"Haemoblock" application
SponsorRyazan State Medical University
Drug classTopical hemostatic agent
ModalitySmall molecule
Therapeutic areaHemostasis/Surgery
PhaseFDA-approved

Mechanism of action

Haemoblock functions as a local hemostatic solution applied directly to bleeding surfaces to arrest hemorrhage. It likely works through a combination of mechanisms including physical tamponade, activation of the coagulation cascade, and promotion of platelet aggregation at the wound site. The exact composition and mechanism are proprietary to Ryazan State Medical University.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results